The 21st International Society of Hypertension in Pregnancy (ISSHP) meeting was held in São Paulo, Brazil from 23 to 26 October 2016. The discourse at this Congress brought global maternal health into the foray among basic science and clinical research. In concordance with the United Nations sustainable development goals which warrant an integrated view to health with investments in adolescence and childhood, the research at Congress focussed on a ‘life course’ approach to maternal health – examining intergenerational effects of maternal obesity and hypertension on the behavioral and physical developments of infants. Bringing in research from the Global South highlighted inequities in treatment and management of women with hypertensive disorders of pregnancy, in addition to the challenges in adoption of recommendations generated in Global North. The evidence shared can serve as platform for further discourse on global maternal health and in generating accountability to close the ‘evidence to policy’ gap.
KassebaumNJBetrozzi-VillaACoggeshallMS. Global, regional, and national levels and causes of maternal mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet2014; 284: 980–1004.
AdoyiGIshakuSMBabatundeOA. A comparative study of knowledge, attitudes and perceptions of women and men around pre-eclampsia and eclampsia in Nigeria. Pregnancy Hypertens2016; 6: 169–169.
4.
KanijSNurRHossainS. Community perceptions of hypertensive disorders of pregnancy, health-seeking behaviors and pathways to seeking care in Bangladesh: preeclampsia in low and middle income countries. Pregnancy Hypertens2016; 6: 196–196.
5.
AdoyiGIshakuMSBabatundeOA. Persisting challenges in the provision of quality obstetric care to women with pre-eclampsia and eclampsia in Nigeria: assessment of health providers’ preparedness and facility readiness: Prevention of preeclampsia. Pregnancy Hypertens2016; 6: 158–158.
6.
MageeLAvon DadelszenPGanzevoortW. for the CHIPs Study Group. Is BP level achieved related to maternal and perinatal outcomes? A secondary analysis of BP values from the CHIPS (Control of Hypertension in Pregnancy Study) randomised controlled trial. Pregnancy Hypertens2016; 6: 138–138.
7.
MillerSEAbalosEChamillardM. Beyond too little, too late and too much, too soon: a pathway towards evidence-based, respectful maternity care worldwide. Lancet2016; 388: 2176–2192.
8.
MaiaLKDa GamaSGNPereiraMN. Analysis of obstetric care during delivery in hypertensive women in Brazil: “WHO” and millennium goals. Pregnancy Hypertens2016; 6: 224–224.
9.
SouzaJBetranADumontA. A global reference for caesarean section rates (C-Model): a multicountry cross-sectional study. BJOG2015; 123: 427–436.
10.
OliveiraLLegramandiOPeraçoliJC. Fullpiers application on the Brazilian practice – a first look shows the need for cultural change within the obstetric workforce: management of preeclampsia, delivery. Pregnancy Hypertens2016; 6: 204–206.
11.
von DadelszenPPayneBLiJ. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet2011; 377: 219–227.
DuckworthSChappellLCGriffinM. Plasma Placental Growth Factor (PlGF) in the diagnosis of women with pre-eclampsia requiring delivery within 14 days: the PELICAN study. BJOG2013; 120: E1–E2.
14.
DavisGKRobertsLHarveySB. Hypertension in pregnancy: gaining insight into women’s mental health and birth experience 6-12 months postpartum. Pregnancy Hypertens2016; 6: 164–164.
15.
IshakuSMIsmailSMAdoyiG. Knowledge and practices for the prevention of pre-eclampsia (PE) among frontline health care providers in Bangladesh and Nigeria: a call for action: prevention of preeclampsia. Pregnancy Hypertens2016; 6: 219–220.
16.
AdepojuAAVidlerMJaiyesimiE. The ability and safety of community-based health workers to initiate lifesaving therapies for pre-eclampsia in Ogun State, Nigeria: an analysis of 294 community treatments with MGSO4 and/or methyldopa: preeclampsia in low and middle income countries. Pregnancy Hypertens2016; 6: 185–185.
DuffyJMNHirschMKawsarA. Completeness of outcome and outcome measure reporting across seventy-nine randomised trials, 31,615 participants, evaluating therapeutic interventions for pre-eclampsia: a systematic review. Pregnancy Hypertens2016; 6: 148–148.
19.
DuffyJMNvan ‘t HooftJGaleC. A protocol for developing, disseminating, and implementing a core outcome set for pre-eclampsia. Pregnancy Hypertens2016; 6: 274–278.
20.
CurranEAKhashanASO’KeeffeGW. Hypertension in pregnancy and autism spectrum disorder in a British cohort: long term consequences for mother and child. Pregnancy Hypertens2016; 6: 153–153.
21.
MageeLASynnesAvon DadelszenP. on behalf of CHIPS-CHILD Working Grp. CHIPS-Child: testing the developmental programming hypothesis in the offspring of the CHIPS trial: randomized trials. Pregnancy Hypertens2016; 6: 143–143.
22.
DavisGKRobertsLCraigM. Physical and developmental health six months postpartum in infants of women with a normotensive versus hypertensive pregnancy. Pregnancy Hypertens2016; 6: 248–249.
BrowneJLKlipstein-GrobuschKKosterMPH. Pregnancy associated plasma protein-A and placental growth factor in a sub-Saharan African population: a nested cross-sectional study: risk factors, and prediction of preeclampsia. Pregnancy Hypertens2016; 6: 172–173.
